Merck (MRK) Intangibles (2009 - 2026)
Merck's (MRK) quarterly Intangibles came in at $25.0 billion in Q2 2026, up 64.4% year-over-year from $15.2 billion in Q2 2025, and down 2.98% quarter-over-quarter from $25.7 billion in Q1 2026.
Analysis
Merck (MRK) Intangibles (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Intangibles for 18 consecutive years, with $25.0 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Intangibles rose 64.4% year-over-year to $25.0 billion in Q2 2026; TTM through Jun 2026 was $25.0 billion, a 64.4% increase from a year earlier, with the FY2025 full-year figure at $26.7 billion, up 62.99% from the prior year.
- Intangibles was $25.0 billion for Q2 2026 at Merck, down from $25.7 billion in the prior quarter.
- Over five years, Intangibles peaked at $26.7 billion in Q4 2025 and troughed at $15.2 billion in Q2 2025.
- A 5-year average of $19.7 billion and a median of $19.4 billion in 2023 frame the typical range for Intangibles.
- Across the five-year window, Intangibles surged 65.15% in 2022 and fell 13.75% in 2023, its largest moves.
- Over 5 years, Intangibles stood at $20.3 billion in 2022, then retreated by 11.14% to $18.0 billion in 2023, then declined by 9.11% to $16.4 billion in 2024, then soared by 62.99% to $26.7 billion in 2025, then dropped by 6.38% to $25.0 billion in 2026.
- The last three Intangibles figures came in at $25.0 billion (Q2 2026), $25.7 billion (Q1 2026), and $26.7 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 47.05 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 30.64 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 63.28 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 103.20 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 2.23 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.98 Bn |
| Mar 31, 2026 | 25.75 Bn |
| Dec 31, 2025 | 26.68 Bn |
| Sep 30, 2025 | 15.31 Bn |
| Jun 30, 2025 | 15.19 Bn |
| Mar 31, 2025 | 15.76 Bn |
| Dec 31, 2024 | 16.37 Bn |
| Sep 30, 2024 | 17.01 Bn |
| Jun 30, 2024 | 16.98 Bn |
| Mar 31, 2024 | 17.57 Bn |
| Dec 31, 2023 | 18.01 Bn |
| Sep 30, 2023 | 19.20 Bn |
| Jun 30, 2023 | 19.67 Bn |
| Mar 31, 2023 | 19.86 Bn |
| Dec 31, 2022 | 20.27 Bn |
| Sep 30, 2022 | 21.37 Bn |
| Jun 30, 2022 | 22.50 Bn |
| Mar 31, 2022 | 23.02 Bn |
| Dec 31, 2021 | 22.93 Bn |
| Sep 30, 2021 | 13.38 Bn |